| Clinical data | |
|---|---|
| Other names | 1P-MIPLA; 1-Propanoyl-lysergic acid methylisopropylamide; 1-Propanoyl-MiPLA; N,6-Dimethyl-1-propanoyl-N-(propan-2-yl)-9,10-didehydroergoline-8β-carboxamide |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C23H29N3O2 |
| Molar mass | 379.504 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
1P-MiPLA, also known as 1-propanoyl-lysergic acid methylisopropylamide (1-propanoyl-MiPLA), is a designer drug and presumed serotonergic psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD). It is the 1-propanoyl derivative of MiPLA and may act as a prodrug of MiPLA. 1P-MiPLA has been discussed on specialized online forums since 2018. In addition, a designer drug product labeled "1P-MiPLA" but actually containing MiPLA was encountered in Austria in 2019.
1P-MiPLA is a controlled substance in Canada under phenethylamine blanket-ban language.
1P-MiPLA is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
| Ergolines (incl. lysergines) |
|
|---|---|
| Clavines (6,8-dimethylergolines) | |
| Lysergamides (lysergic acid amides) |
|
| Ergopeptines (peptide ergolines) |
|
| Partial ergolines |
|
| Related compounds | |
| Natural sources |
|